Levosimendan Kabi

Levosimendan, the active ingredient in Levosimendan Kabi, is a calcium sensitizer presented as an intravenous solution for intravenous use. It enhances myocardial contractility and promotes vasodilation, making it indicated for the treatment of acute decompensated heart failure in hospitalized adults.

GNH USA supplies Levosimendan Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. All batches are manufactured under GMP standards and undergo rigorous quality testing before release. The company ensures cold‑chain logistics where required to maintain product integrity.

Levosimendan is used in the management of acute decompensated heart failure, a condition characterized by sudden worsening of cardiac function.

- Acute decompensated heart failure: improves cardiac output and reduces symptoms of congestion. - Severe chronic heart failure (adjunct therapy): provides hemodynamic support when standard treatments are insufficient. - Post‑cardiac surgery low output syndrome (off‑label): may enhance myocardial performance in patients with postoperative cardiac dysfunction.

Levosimendan may cause several adverse reactions that clinicians monitor during therapy.

Common Side Effects: - Headache: mild to moderate intensity. - Hypotension: transient drop in blood pressure. - Nausea: occasional gastrointestinal upset. - Tachycardia: increased heart rate.

Serious or Rare Side Effects: - Ventricular arrhythmias: potentially life‑threatening rhythm disturbances. - Myocardial ischemia: reduced blood flow to heart muscle. - Severe hypotension: marked blood pressure decline requiring intervention. - Allergic reactions: rash, pruritus, or anaphylaxis.

Levosimendan requires careful monitoring and specific precautions before and during administration. - Blood pressure monitoring: observe for hypotension and adjust infusion rate. - Cardiac rhythm surveillance: watch for arrhythmias, especially in patients with pre‑existing conduction disorders. - Dose adjustment: consider renal or hepatic impairment when determining infusion parameters. - Contraindication in severe hypotension: avoid use in patients with markedly low blood pressure. - Hypersensitivity: discontinue if signs of allergic reaction occur. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the solution.

Levosimendan can interact with other medications, necessitating awareness of potential additive effects.

Major Interactions (Avoid): - Concurrent vasodilators: may cause profound hypotension. - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase levosimendan exposure. - Other calcium sensitizers: risk of excessive inotropic effect.

Moderate Interactions (Monitor Closely): - Diuretics: may amplify volume depletion and blood pressure changes. - Beta‑blockers: can blunt desired inotropic response. - ACE inhibitors or ARBs: require blood pressure monitoring for additive effects.